CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $4.64 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.